Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications.

Transpl Int · 2024 · PMC11345135 · PMID 39188271

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Similarly, a single-center report described dd-cfDNA to assess treatment response of the monoclonal anti-IL-6-receptor antibody tocilizumab in patients with AMR and observed a significant decrease in dd-cfDNA, potentially reflecting resolving injury, but only a nonsignificant trend in proteinuria reduction [ 76 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.